Company intelligence / Profile preview
Promore Pharma
Swedenpromorepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Promore Pharma was developing therapeutic peptides for wound care, with ensereptide (PXL01) for preventing post-surgical adhesions and dermal scarring, and ropocamptide (LL-37) for treating chronic leg ulcers. However, the company entered into voluntary liquidation in October 2023.
- Therapeutic areas
- OtherDermatologyInfectious Diseases
- Modalities
- Therapeutic peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Promore Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promore Pharma.